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Summary 
 
Identification of growth suppressive genes as cyclin A1 targets in 
acute myeloid leukemia by microarray analysis 
 
Amber Yasmeen 
 
Cyclin A1 is a tissue specific A-type cyclin, which is essential for spermatogenesis. Cyclin A1 
is also highly expressed in blasts of acute myeloid leukemia. In a transgenic mouse model, 
cyclin A1 induced leukemia but its pathogenic role and the molecular mechanisms of its 
action remain unclear. In this study, we identified cyclin A1 induced genome wide changes in 
gene expression. RNA from U937 control vector transfected and cyclin A1 overexpressing 
U937 cells were analyzed at different serum conditions using high-density oligonucleotide 
arrays. A number of genes, which showed upregulation and downregulation by cyclin A1, 
were identified. WT1 and EGR1, two growth suppressor were downregulated by cyclin A1. 
This finding was confirmed by quantitative RT-PCR analysis. Furthermore, WT1 was shown 
to be downregulated at the protein level in U937 cells overexpressing cyclin A1 as compared 
to control cell lines. We also analyzed the expression of WT1 and EGR1 in different leukemia 
cell lines at the protein level. Expression of WT1 protein was low in Hutu, KCL22, ML1 and 
Cos cells. EGR1 protein was low in ML1, KCL22 and NB4.  In cyclin A1-/- mice organs, WT1 
and EGR1 were higher expressed in testis, bone marrow and ovary as compared to the wild 
type organs. Also, cyclin A1-/- murine embryonic fibroblasts (MEFs) expressed higher levels 
of EGR1 mRNA upon irradiation than irradiated wild type fibroblasts. WT1 and EGR1 protein 
levels were increased in cyclin A1-/- MEFs. Four different isoforms are known of WT1, which 
are characterized by the insertion or exclusion of two splice inserts (17aa and KTS) at two 
different positions. Interestingly, in U937 control cells the WT1-/- isoform was found 
predominantly. In U937 cells overexpressing cyclin A1, all isoforms WT1-/-, WT1+/+, WT1+/- 
and WT1-/+ could be found. The WT1-/+ isoform reduced colony formation and induced G1 
cell cycle arrest in a myeloid cell line. 
Taken together, cyclin A1 overexpression in U937 myeliod cells leads to significant changes 
in genome wide gene expression. WT1 and EGR1 are putative cyclin A1 target genes. These 
data provide evidence that cyclin A1 can lead to transcriptional suppression of tumor 
suppressor and antiproliferative genes. 
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1. Introduction 
1.1 Cyclins and Cell Cycle 
The cell cycle is based on two key families of proteins. First, the family of cyclin-
dependent protein kinases (cdks) activates downstream signaling by phosphorylating 
substrates at serine and threonine residues. Second, a family of specialized 
activating proteins, called cyclins, binds to cdk molecules and control their ability to 
phosphorylate appropriate target proteins.  
The cyclic assembly, activation and disassembly of cyclin-cdk complexes are pivotal 
events driving the cell cycle. The name “cyclin” is based on the oscillating synthesis 
and degradation in each cell cycle division (101, 154) (126) (33). Cdks and their 
cyclin partners are positive regulators, which induce cell cycle progression. Cyclin 
dependent kinase inhibitors act as brakes to stop the cell cycle progression in 
response to regulatory signals. By direct association with cyclin-cdk complexes, 
cyclin dependent kinase inhibitors can downregulate  cdk activity (73, 155). 
 
The binding of two families of cyclin dependent kinase inhibitors modulates the 
activity of cdks. The first class includes the INK4 proteins, which specifically inhibit 
the catalytic subunits of cdk4 and cdk6. There are four such proteins named p16INK4A, 
p15INK4B, p18INK4C and p19INK4D (73, 156) consisting of multiple ankyrin repeats and 
which bind specifically to cdk4 and cdk6.  
 
The second class (Cip/Kip) affects the activities of cyclin D, E and A dependent 
kinases. The Cip/Kip family includes p21Cip1, p27Kip1 and p57Kip2, all of these contain 
characteristic motifs within their amino-terminus that enable them to bind both to 
cyclin and cdk subunits (47, 155). 
 
Cyclins were first identified in marine invertebrates on the basis of their involvement 
in  cell cycle periodicity during meiotic and early mitotic divisions (127, 162). There 
are 30 cyclin sequences in higher vertebrates named cyclins A-H, which are divided 
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into different categories. The cyclins A to H can be distinguished on the basis of 
conserved sequence motifs, by pattern of appearance as well as by different 
functional roles during specific phases of the cell cycle (reviewed in (125, 153) (156)). 
 
The activity of cyclins usually requires physical association with cyclin dependent  
serine and threonine kinases (cdks). In mammalian cells, several cdks (cdk2, 3, 4, 5, 
6 and 7) function at different stages of the cell cycle and their activities are regulated 
by cyclins, various co-factors and modifying enzymes. The negative regulators, so 
called cyclin-dependent kinase inhibitors (CKIs) bind to the cyclin and to cdk subunits 
inhibiting kinase activity and cell cycle progression (47, 135, 152, 156). 
 
The cell cycle is comprised of different stages G1, S, G2, and M division. Cell cycle 
regulation depends on the balance between the presence of activated cyclins, 
activated cyclin dependent kinases and kinase inhibitors. Active cyclin-cdk 
complexes enable the cell to pass through specific phases of the cell cycle division 
(G1 and G2), DNA synthesis (S), and mitosis (M). Cyclin abundance is rate limiting 
for progression through the different stages of the cell cycle, e.g. progression through 
G1 depends upon cdk4 and cdk6 along with cyclin D regulatory subunits. D type 
cyclins are synthesized in early G1, bind to and activate cdk4 and cdk6 in response 
to mitogenic signals.  
 
 
Subsequently, cyclin E interacts with cdk2 and regulates late G1 and early S Phase 
(25, 118) Cyclin A2 appears later in the cell cycle, interacting with cdk2 and cdk1, 
and regulating progression through S phase and early G2 phase. Cyclin B is active 
during mid-G2 and mitosis when it forms a kinase complex with cdk1 (Figure 1). 
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Figure 1: Expression of cyclins oscillates during cell cycle progression 
Transcription of cyclin genes is induced in specific cell cycle phases. Also, co-
ordinated cyclin degradation is crucial for cell cycle progression (122) 
 
1.2 The Role of A-Type Cyclins in Cell Cycle 
 
1.2.1   Cyclin A2 
 
The A-type family of cyclins consists of two members: cyclin A1 and cyclin A2. Cyclin 
A2 (formerly known as cyclin A) can activate two different cyclin-dependent kinases. 
Cyclin A2 accumulates in the nucleus immediately after its synthesis and associates 
with both cdc2 (cdk1) and cdk2 (29, 40, 64, 120). In tissue culture systems, the 
activity and localization of cyclin A2 support the hypothesis that it binds to both cdk2 
and cdc2 (cdk1) (55) (13). This leads to two distinct cyclin A2 associated kinase 
activities, one appearing in S phase, the other in G2. In addition to its role in S phase 
progression, cyclin A2 is also involved in G2/M transition and mitosis. Cyclin A2 has 
been reported to be expressed in meiotically arrested oocytes of several species, 
including fish (60) and frogs (49). In addition, cyclin A2 is a rate limiting component 
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for entry into mitosis (79, 117). Cyclin A2 deficient cells do not enter mitosis (75). 
Cyclin A2 acts earlier in the cell cycle than cyclin B (54, 63) 
 
In Drosophila embryos, cyclin A2 mutations cause defects in neuronal progenitor 
cells (167). During mouse embryogenesis, cyclin A2 is present at high levels, (133, 
161) and targeted mutagenesis of the coding region of murine cyclin A2 results in 
early embryonic lethality, apparently around the preimplantation stage (109). Somatic 
and germ cells of the ovary express cyclin A2 mRNA and protein, while cyclin A2 is 
not found in the oocyte and metaphase II arrested egg. Nonetheless, cyclin A2 is 
detected after fertilization and throughout the preimplantation development stages. 
Mouse cyclin A1 and A2 share 44% overall similarity at the amino acid level and  
(84%) amino acid identity within the highly conserved cyclin box (133, 161, 172). 
 
Cyclin A2 regulation has been studied in different cell culture systems. Cyclin A2 is 
synthesized at the onset of DNA replication as well as during G2/M transition (151). 
Cyclin A2 expression is under negative transcriptional control during the cell cycle 
especially in G0 and early G1 phase while repression is not observed in later phases. 
Cyclin A2 expression is required for transcriptional derepression of its own gene. An 
inhibitory complex is found at the promoter in vivo and in vitro (53, 147, 180). The 
region responsible for repression has been named CDE (cell cycle dependent 
element) and CCRE (cell cycle responsive element). The cyclic association and 
dissociation of CDE/CCRE  repressor complex is involved in the periodic 
transcription of cyclin A2. Another region in the cyclin A2 promoter named CHR (Cell 
cycle genes homology region) shows homology with sequences in the promoter of 
several other cell cycle regulated genes (181). This cell cycle gene homology region 
(CHR) is found in the promoters of cdc25C, B-myb, cdc2 and cyclin A2. In gel shift 
experiments, binding to the major DNA groove for the CDE/CCRE and to the minor 
groove of the CHR has been shown (53, 87, 88, 123). Mutation of either motif results 
in de-repression of the cyclin A2 promoter.  
E2F plays critical roles in cell cycle progression by regulating the expression of 
genes involved in nucleotide synthesis, DNA replication, and cell cycle control. E2F is 
a heterodimeric transcriptional factor composed of the E2F and DP multi-gene 
families (105, 115). Transcriptional activation by E2F is modulated during the cell 
cycle by pocket proteins of the pRb family (116). E2F is repressed in G0 and early 
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G1, but during cell cycle progression cyclin dependent kinases effect the dissociation 
of the inhibitory E2F pocket protein complexes. This dissociation generates 
transcriptionally active free E2F and leads to the activation of E2F –regulated genes 
(72, 105, 115). E2F plays no significant role in the repression of cyclin A2 promoter in 
G0/G1 cells, but later in the cell cycle. E2F1 and E2F3 bind the CDE and displace a 
presumed repressor protein named CDF1 in late stage of G1/S phase (182) (86). 
Mutation in the CDE can abrogate the binding of E2F, and overexpression of E2F1 
leads to an upregulation of the cyclin A2 gene (20, 21, 147). Cyclin A2 promoter 
activity is repressed by the CHR/CHR-binding factor (CHF) (123). The repressor 
elements are thought to interfere with the transactivation function of factors bound 
further upstream. Sp1, NF-Y, and CBP/cycA and the ATF/CREB/CREM family can all 
interact with upstream elements (20, 180, 183). The ATF/CREB/CREM family factors 
mediate regulation of the cyclin A2 promoter by cAMP (22). It was also reported that 
ATF/CREB/CREM family members show cell type specific binding to the cyclin A2 
promoter (6). CBP/cycA is involved in adhesion-dependent cyclin A2 transcription 
(66). 
 
The overexpression of viral proteins such as Adenovirus E1A, Simian virus 40, 
human herpesvirus-8 (HHV-8) and Polyoma T antigens or Papilloma E7 has been 
shown to increase cyclin A2 expression by binding to the CCRE/CDE-CHR. These 
findings further support to the notion that pocket proteins may modulate cyclin A2 
transcription (27, 146, 178, 179). 
 
The Retinoblastoma gene product (pRb) and the related p107 and p130 interact with 
cyclin A2. They are essential for repression of cyclin A2 in quiescent cells and play a 
role in early G1 phase and G1/S transition (124). The C-terminal regulatory domain 
of p53 contains a cyclin A2-cdk2 docking site, which suggests a role for cyclin A2 in 
p53 responses to DNA damage (89). Cyclin A2/cdk2 bind to E2F transcription factors 
(E2F-1, 2, 3A, 3B) in vivo and in vitro and modulates E2F activity by phosphorylation 
(147). In G1, CDC6 interacts specifically with the active cyclin A2/cdk2 complex in 
vitro and in vivo. Nuclear CDC6 relocalizes to the cytoplasm upon cyclin A2/cdk2 
activation. This negative regulatory event could be implicated in the prevention of re-
replication during S phase and G2 (16). Jun B and B-myb are also physiological 
targets for cyclin A2/cdk2. B-myb has been implicated in regulation of cell cycle
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 progression especially during S phase. Cyclin A2/cdk2 (141) enhances its 
transactivation capacity. Cell adhesion plays an essential role in the regulation of 
cellular proliferation. It was observed in both NRK and NIH3T3 fibroblasts that cyclin 
A2 is a target of adhesion dependent signals (20). Also, activation of human primary 
T lymphocytes via CD2 and CD28 adhesion molecules relieves Cyclin A2 gene 
transcriptional inhibition (128). Ectopic expression of c-myc causes deregulation of 
cyclin A2 levels and adhesion independent growth. Cyclin A2 is critically involved in 
chromosome ploidy, and mutations have been shown to be associated with endo-
reduplication in certain cells, and silencing of cyclin A2 induces complete genome 
duplication (96). In mammalian somatic cells, cyclin A2 is also involved in the 
centrosome duplication. This requires phosphorylation of retinoblastoma protein (Rb), 
E2F transcription factors and cdk2 activity (95). 
 
1.2.2 Cyclin A1 
 
Cyclin A1 was isolated and characterized as a second human cyclin A gene (133, 
161, 172, 175). Cyclin A1 has 48% identity with human cyclin A and is more related 
to the recently cloned murine cyclin A1 (84% identity). Cyclin A1 is specifically 
expressed in testis and brain. It is also highly expressed in several myeloid leukemia 
cell lines, including ML-1, U937, NB4, KG-1, and THP1. In contrast, very low 
expression at the mRNA level is observed in most nonleukemic, adherent cell lines 
(175).  
 
There are different roles for the two A-type cyclins in the regulation of mitotic and 
meiotic cell cycles (133, 161). The mRNAs of the putative cdk partners of these 
cyclins, cdk1 and cdk2 are expressed in similar patterns during spermatogenesis 
(173). Murine cyclin A1 binds both cdk1 and cdk2 in testis (83, 84, 161). Cdk2 is 
highly expressed during all stages of spermatogenesis, especially in cells undergoing 
the meiotic reduction division. It was also reported that in testicular cells cdk1 is not 
the active partner of cyclin A1 (134) a fact confirmed by a yeast two-hybrid assay that 
showed human cyclin A1 does not interact with cdk1 (175). 
 
The importance of cyclin A1 for spermatogenesis was demonstrated in a deletional 
mouse model (85). Male cyclin A1-/- mice are sterile due to a block of 
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spermatogenesis before the first meiotic division. This meiotic arrest is associated 
with increased germ cell apoptosis, synaptic abnormalities and reduction in cdc2 
kinase activation at the end of the meiotic prophase. Besides defects in 
spermatogenesis, cyclin A1-/- mice develop normally, suggesting that cyclin A1 is not 
essential for embryonic and postnatal somatic cell division (109). Female cyclin A1-/- 
mice do not show noticeable defect during oogenesis, which indicates differences of 
regulatory mechanisms of meiosis between male and female. 
 
Cyclin A1 expression is regulated at the transcriptional and translational level during 
cell cycle. The human cyclin A1 promoter initiates transcription from several sites and 
a construct containing a fragment from -190 to +145 shows the highest transcriptional 
activity. Promoter activity crucially depends on four GC boxes upstream of the 
transcriptional start sites. These GC boxes, which are binding site for Sp1 and Sp3 in 
vitro also regulate cell cycle regulated expression (103). Hypomethylation of the 
cyclin A1 promoter is important for the high transcriptional promoter activity in 
leukemia cell lines. Although tumor cells often express aberrant methyltransferase 
activity (61, 168), they have been shown to display hypomethylation of promoter 
regions of genes that promote growth and inhibit apoptosis (43). Methylation of the 
cyclin A1 promoter correlates with absence of endogenous cyclin A1 expression in 
solid cancer cell lines.  
 
Functionally, cyclin A1 associates with the cell cycle regulatory proteins Rb and E2F1 
in vivo and in vitro. Also, Rb family proteins and E2F1 are substrates for 
phosphorylation by cyclin A1 associated kinases (176). Cyclin A1 also interacts with 
B-myb. Cyclin A1/cdk2 posphorylates B-myb at functionally important serine and 
threonine residues in the C-terminus (106). Since B-myb is important for proliferation 
of normal hematopoietic and leukemia cells, cyclin A1 may be one of the co-
activators that enable the transactivating ability of B-myb in these cells. C-myb is also 
involved in the transactivation of the human cyclin A1 promoter. This interaction 
shows a specific involvement of c-myb in the cell cycle of the hematopoietic cells. 
Thesed data provide evidence that cyclin A1 interacts with cell cycle regulatory 
proteins and all these findings suggest that Cyclin A1 has a distinctive role in the cell 
cycle of somatic cells (104). 
However, most genes regulated by cyclin A1-cdk2 have not been identified, yet.
Introduction 10    
 
 
 
 
 
Figure 2: Regulation of Rb by cyclin/cdk complexes 
Regulation of the Rb/E2F pathway by cyclin/cdk2 complexes is well established and 
is shown here to illustrate the principle of cyclin/cdk action. Mitogenic signals induce 
the synthesis of cyclin D and subsequent formation of cyclin D-cdk4/6 complexes. 
The cyclin D- cdk4/6 complexes then phosphorylate downstream targets, including 
Rb protein. Cyclin D-cdk4/6 activity leads to the activation of cyclin E-cdk2 
complexes. Increased cyclin E-cdk2 kinase activity then results in enhanced Rb 
phosphorylation. Rb hyperphosphorylation releases E2F from transcriptionally 
repressive Rb/E2F complexes. E2F downstream genes lead to S phase initiation. Rb 
is also phosphorylated by cyclin A/cdk2. Cyclin/cdk activity is regulated by several 
cdk inhibitors and other regulatory factors e.g. cyclin activating kinase (CAK).  
 
1.3 Acute Myeloid Leukemia 
Acute myeloid leukemia (AML) is a malignant disease of the hematopoietic system. 
AML is characterized by an accumulation of granulocyte or monocyte precursors in 
the bone marrow and blood. Although leukemia originates from the bone marrow, it 
can spread to the blood, lymph nodes, spleen, liver, central nervous system and 
other organs. In Germany, the annual incidence of AML is about 2-5 per 100.000 
humans and increases with increasing age on up to 12 per 100.000 humans at the 
age of > 65 years. In the past years, progress was made with investigating of 
characteristic genetic changes of AML blasts. Their association with clinical and 
prognostic characteristics and functional consequences were defined. Recent 
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findings led to the refinement and revision of the diagnostic criteria, influencing the 
new WHO classification of the disease (45). 
 
1.3.1 Acute Myeloid leukemia- Diagnosis 
 
 
 
The diagnosis of AML is based on the presence of more than 30% blasts in the bone 
marrow of the patient.  AML is divided on the basis of morphological and 
cytochemical characteristics according to the French American British (FAB) - 
classification in sub-groups (see Table 1). 
 
FAB-Classification in Acute Myeloid Leukemia 
FAB Name Percentage MPO NBE PAS Associated 
Translocation 
 Involved 
 Gene 
M0 Undifferentiated  3% - - - inv(3q26), t(3;3) 
(1%) 
EVI1 
M1 Myeloblastic without 
maturation 
 +/- - -   
M2 Myeloblastic with 
maturation 
25-30% ++ - - t(8;21) (40%)  AML1/ETO 
      t(6:9) (1%)  DEK/CAN 
M3 Acute Promyelocyctic 
leukemia 
5-10% +++ - +/- t(15;17) (98%)  PML/RAR?  
      t(11;17 (1%)  PLZF/RAR?  
      t(5;17) (1%)  NPM/RAR? ?
M4 Acute myelomonocytic 
Leukemia 
20% +++ ++ - 11q23 (20%)  MLL 
      inv(3q26), t(3;3) 
(3%) 
EVI1 
      t (6; 9) (1%)  DEK/CAN 
M4eo Myelomonocytic with 
bone marrow eosinophlia 
5-10% +++ ++ - inv(16), t(16;16) 
(80%) 
CBFß/MYH
11 
M5 Acute Monocyticleukemia 2-9% +/- +++ +/- 11q23 (20%)  MLL 
      t(8;16) (2%)  MOZ/CBP 
M6 Erythroleukemia 3-5% - - +++   
M7 Acute Megakaryoblastic 
leukemia 
3-12% - - ++ t(1;22) (5%)  GATA1 
mutations 
Table :1 FAB-classification of AML; MPO=Myeloperoxidase; NBE=N-Butylacetat-
Esterase (unspecific); PAS=Periodic-acid Shift 
 
Apart from this classification the international commission has developed new AML 
classification for World Health Organization (WHO) (45). Within each category, 
distinct diseases are defined according to a combination of morphology, 
immunophenotype, genetic features and clinical syndromes (See Table: 2).
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WHO-classification of Acute Myeloid Leukemia:  
AML with recurrent cytogenetic translocations 
 AML with t (8; 21)(q22; q22), AML1/ETO 
 Acute Promyelocytic leukemia (AML with t (15; 
17)(q22; q11-22) and Variants, PML/RAR? ) 
 AML with abnormal bone marrow eosinophils 
(inv (16)(p13q22) or t (16; 16(p13; q11), CBFß/MYH11) 
 AML with 11q23 (MLL)-Abnormalities 
  
AML with multilineage dysplasia 
 With prior myelodysplastic syndrome 
 Without prior myelodysplastic syndrome 
 
AML and myelodysplastic syndromes, therapy related 
 Alkylating agent-related 
 Epipodophyllotoxin-related (some may be lymphoid) 
 Others type 
 
AML not otherwise characterized 
 AML minimally differentiated 
 AML without maturation 
 AML with maturation 
 Acute myelomonocytic Leukemia 
 Acute monocytic Leukemia 
 Acute erythroid Leukemia 
 Acute megakaryocytic Leukemia 
 Acute Basophilic leukemia 
 Acute Panmyelosis with myelofibrosis 
 Acute biphenotypic Leukemia 
 
Table 2: WHO-classification of AML 
 
In this classification, cytogenetic and pathogenetic criteria of the AML are taken into 
account, which determine prognosis and in the future also selection of therapy. The 
analysis of AML typical mutations and the identification of antigens on the surface of 
AML blasts and specific chromosome translocations have improved classification. 
The classification AML is facilitated by the powerful and well-developed techniques of 
cytogenetics, fluorescence in situ hybridization (FISH) and polymerase chain reaction 
(163). The cyctogenetics, FISH and PCR techniques enable the detection of 
quantitatively molecular changes or chromosomal translocations in leukemia cells 
and allow highly sensitive detection of remaining blasts in patients undergoing 
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remission. Progress in prognosis and treatment of childhood leukemia are 
considered as a remarkable success of modern medicine. Childhood leukemia, once 
was considered as a fatal disease, now exhibits overall cure rates ranging from 75% 
to 85% for acute lymphocyte leukemia and 40% to 50% for acute myelogenous 
leukemia (15). 
 
1.3.2 Acute Myeloid leukemia - prognosis factors 
 
A set of clinical and molecular characteristics indicates both the probability of 
achieving complete remission and the duration of disease-free survival of AML 
patients.  
 
According to another classification of AML (MRC) patients are divided into 
favourable, intermediate and unfavourable subtypes based on the prognosis (see 
Table 3). 
Medical Research Council (MRC) classification of AML 
 Subtype           MRC MRC and C/EBP?  mutation status 
Favorable T(15; 17),Inv(16),t(8;21) t (15,17), Inv (16) and t (8; 21), or C/EBP?  
mutation without FLT3-ITD or adverse 
cytogenetics 
Intermediate  All others C/EBP?  mutation with FLT3-ITD or all 
others 
Unfavorable del (5q)/-5, -7,3q;complex 
karyotypic abnormalities 
del (5q)/-5, -7,3q;complex karyotypic 
abnormalities 
Table 3: MRC-classification of AML; C/EBP?  = CCAAT/enhancer binding protein-
? ;ITD, internal tandem duplication. Modified from ref (41). 
 
 It has to be considered that the choice of the therapy is different among above-
mentioned classification based on prognosis. The prognosis of the AML M3 with the 
translocation t (15; 17) is quite favourable upon treatment with conventional 
chemotherapy, the specific therapy with ATRA finally leads to excellent survival 
rates. Patients with the translocation t (8; 21) seem to have a more favourable 
prognosis upon the repeated application of high dose ARA C (10).  
However, also the mortality of patients with favourable karyotype still reaches 40% to 
50%. Secondary AML after MDS (myeloid dysplastic syndrome) and/or after the 
treatment with chemotherapeutic agents (i.e. Alkylation and Topoisomerase II-
inhibitors) leads to a significantly worse prognosis than those of the average of the 
leukaemiapatients. 
Introduction 14    
 
 
 
Many genes and signalling pathways are involved in development of AML. It was 
observed that high levels of cyclin A1 were found in AML cell lines and in AML 
samples from patients (175, 177). This observation suggests a possible role of cyclin 
A1 in AML and in the proliferation and differentiation of hematopoietic progenitors. 
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2. Materials & Methods 
 
2.1 RNA extraction and hybridization 
Total RNA was extracted from cells using TRIzol reagent (Invitrogen). 10 µg of total 
RNA were reverse transcribed into cDNA using an oligo-d (T)-T7-primer. 
Subsequently, T7 polymerase was used for in vitro transcription. During transcription, 
cRNA was labelled using biotinylated oligonucleotides. The resulting labelled cRNAs 
were fragmented and hybridized to U95A oligonucleotide microarrays, containing 
probes for approximately 12000 independent transcripts (Affymetrix, Santa Clara, 
CA). Arrays were scanned following staining with streptavidin-phycoerythrin, signal 
amplification with biotinylated anti-streptavidin antibodies and subsequent staining 
with streptavidin-phycoerythrin. Raw data were normalized and scaled to an average 
level of 2500. 
2.2 Analyses of microarray data and bio informatics  
Bioinformatical analyses were performed using Gene spring analysis software (Gene 
spring). A two-class procedure of the Significance Analysis of Microarrays software 
(Stanford) was used to identify differentially regulated genes (166). The delta value 
was set at 0.59. SPSS 10.0 was used to evaluate the statistical significance of gene 
expression differences. 
 For a gene to be classified as repressed, its expression had to be lower than 50% in 
each of the three different serum concentration samples as compared to U937-
wildtype control and cyclin A1 transfected cells. Finally, gene candidates were 
excluded which were repressed more than 3-fold by U937 control cell vs cyclin A1 
and with 1%, 5% and 10% FCS concentration. For a gene to be called induced, its 
expression had to be increased at least 3-fold in each sample compared to U937-
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control vector vs overexpressing cyclin A1 with different FCS concentration samples 
had to be above 150 units (Affymetrix average intensity). 
2.3 Quantitative real-time RT-PCR 
Total RNA was isolated using TRIzol (Invitrogen) according to the manufacturers 
recommendations from U937 cell line. For RT-PCR, RNA was reverse transcribed 
using M-MLV (Moloney murine leukaemia virus) reverse transcriptase (Promega).  
First, 1?g of RNA was incubated with 1? l RNAse out, in DEPC-H2O (RNAse free 
water) at a total volume of 17,5? l for 5 minutes at 70°C. RNA samples were 
incubated for 5 minutes on ice and again for 10 minutes at room temperature. 1? l of 
M-MLV was added with 5? l of 5x buffer, 1,25? l of dNTP’s and incubated for 1 hour 
at 42°C. After reverse transcription MMLV was inactivated by 70°C for 15 minutes. 
The cDNA samples were diluted to 100? l and 2.5? l of cDNA were used for each 
PCR reaction. PCR-amplification of the housekeeping gene glyceraldehydes-3-
phosphate-dehydrogenase (GAPDH) was used to confirm the quality of cDNA and 
standardize the total amount of cDNA between different samples. The quantification 
of mRNA expression levels was carried out using a real-time fluorescence detection 
method based on TaqMan Instrument (PE Bio systems) (106). 
 
The PCR reactions were prepared with 2x master mix (Applied biosystems) 12.5? l,  
forward and reverse primer (10?m) 0.125? l each, probe (5?m) 0.5? l and ddH2O  
6.75? l. Cycling conditions were 50°C for 5min, 95°C for 2min, 95°C for 2min, and  
60°C for 2min. The steps 3 to 4 were repeated 40 times. The WT1 and EGR1 probes  
were labelled at the 5’ end with the fluorescent dye FAM and the housekeeping gene 
 (GAPDH) with VIC and at the 3’ end with quencher TAMRA.  The 5’ nuclease activity  
of the Taq polymerase cleaved the probe and released the fluorescent dyes (FAM or  
VIC), which was excited by a laser, and the emitted flouresence was detected by a  
CCD camera. After the detection threshold was reached, the fluorescence signal was  
proportional to the amount of PCR product generated. Initial template concentration  
was  calculated from the cycle number when the amount of PCR product passed a  
threshold set in the exponential phase of the PCR reaction. Relative gene expression  
levels were calculated using standard curves generated by serial dilutions of U937  
cDNA. The relative amounts of gene expression were calculated by using the  
expression of GAPDH as an internal standard.  At least three independent analyses 
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were performed for each sample and each gene. Primers and probes are listed in the  
2.9 heading.  
                                     
2.4 Cell Lines and Transfection 
MEF (murine embryonic fibroblasts), Hela (human cervical carcinoma cells), Hutu 80 
(human colon carcinoma cells), NIH3T3 (murine fibroblasts), KCL22 (human chronic 
myeloid leukemia), SW837 (adenocarcinoma cell line), NB4 (human acute 
promyelocyctic leukemia), K562 (human chronic myeloid leukemia in blast crisis), 
ML1 (human acute myelomonocytic leukemia), Cos- 7 (monkey kidney cells). In this 
study, two stable myeloid leukamia cell lines derived from U937 cells (human myeloid 
leukemia) cells were used (gift from Dr. Carmela Beger MHH Hannover). U937 cell 
were transfected with empty retroviral vector pLXSN as a control cell line or with 
pLXSN cyclin A1 mRNA(U937 overexpressing cyclin A1). 
  
Suspension cell lines were grown in RPMI 1640 medium (Invitrogen), and adherent 
lines were maintained in Dulbecco's modified Eagle medium (DMEM, Invitrogen), 
each supplemented with 2 mM L-glutamine and 10% fetal calf serum (FBS, Biochrom 
KG), 100units/ml pencillin and 100?g/ml streptomycin (Biochrom KG), 2mM L-
glutamine (Biochrom KG).  
 
32D myeloid progenitor cells were cultured in RPMI-1640+ 20mM HEPES 
(Invitrogen) supplemented with 10% fetal bovine serum (FBS, Biochrom KG), 100-
units/ml pencillin and 100?g/ml streptomycin (Biochrom KG), and 2mM L-glutamine 
(Biochrom KG). All mammalian cells were grown at 37°C and 5% CO2. 32D myeloid 
progenitor cells were transfected following the Amaxa Kit (biosystems) protocol. A 
total of 5?g of plasmid DNA with 100? l of solution R per transfection was used. The 
cells were electroporated by Amaxa program T24, which was optimized for 32D cells. 
 
2.5 Antibodies & Western blotting 
Cells were lysed in Radioimmunoprecipitation buffer (RIPA) (150mM NaCl, 1.0% NP-
40, 0.5% deoxycholic acid (DOC), 0.1% SDS, 50mM Tris–Cl (pH8.0) with complete 
EDTA-free protease inhibitor). The proteins were run on SDS-PAGE gradient gels (7-
14% Bio-Rad). Proteins sample were electroblotted onto PVDF membranes 
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Immobilon-P (Millipore), probed with specific primary antibodies EGR-1 (588) and 
WT1 (F-6) from Santa Cruz Biotechnology, ? -Actin (Sigma) followed by IgG –
conjugated peroxidase a coupled secondary anti-body against rabbit and mouse IgG 
(Jackson ImmunoResearch). Detection was performed with ECL plus (Amersham 
Biosciences) and exposure to a radiographic film.  
 
2.6 Colony Assay 
U937 control and overexpressing cyclin A1 or 32D cells were electroporated with 
10ug of each pcDNA3, pCMV-EGR1 (pCMV EGR1 is a gift from Milbrandt Lab), 
pcDNA3-cyclin A1, pCMV-WT1+/-, pCMV-WT1-/+, pCMV-WT1-/- and pCMV-WT1+/+ 
expression vectors (WT1 isoforms were a gift from Dr Jerry Peteiller’s Lab). After 16 
hours cells were separated by gradient centrifuge and 1x 105 lived cells per 35mm 
dish were cultured with methylcellulose mix. The methylcellulose mix contained 
“Iscove modified Dulbecco medium” with 1% methylcellulose, 20% FCS, IL3 (1ng/ml) 
and in the presence of blastidin or neomycin (0.5-0.6mg/ml) as a selection marker, 
grown in triplicate in methylcellulose colony assays. Colonies were counted after 14 
days of growth.  
 
2.7 Flow cytometry 
32D cells were transfected with GFP-Ras, pcDNA3, pcDNA3-cyclin A1, pCMV-
EGR1, pCMV-WT1 +/-, pCMV-WT1-/+ expression vectors with Amaxa Kit 
(biosystems) protocol (described previously) and incubated for 24hours. For FACS- 
analysis, cells were washed with PBS and 0.1% BSA, fixed by resuspension in ice-
cold 70% ethanol and incubated on ice for 1 hr. After extensive washing, cells were 
resuspended in PBS containing RNase A and propidium iodide and incubated at 
room temperature for 30 minutes up to 1 hour. FACS analyses were performed using 
FL-1 vs FL-2 channel (GFP vs PI) in order to get the cell cycle profiles of GFP 
positive (transfected) cells. Cell cycle distribution was calculated using the ModFitL T 
V2.0 (PMac) software.    
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2.8 Isoform Analysis 
 
A forward primer labelled with fluorescent dye phosphoramidites FAM 5’CAG-ATG-
AAC-TTA-GGA-GCC-ACC-TTA-A-3’ and the unlabeled reverse primer 5’-TTG-GCC-
ACC-GAC-AGC-TG-3’ were used in the PCR. The cDNA from U937 control and 
U937 cyclin A1 cell line were prepared with MMLV reverse transcriptase (Promega) 
following manufacturers protocol (described previously). Each PCR mixture 
contained 50-100ng of cDNA, 2.5units of taq polymerase, 1?m of each primer, 10um 
each dNTP, 1.5mM MgCl2, and PCR buffer at a 1X final concentration. (Applied 
Biosystem, CA, USA). Thirty cycles of PCR were performed in a DNA-thermal cycler 
(Master cycler personal, eppendorff). After initial denaturation at 95°C for 4 min, each 
cycle consisted of denaturing at 95°C for 4 min, 94°C for 20 seconds, annealing at 
62°C for 20 seconds, and extension at 72°C for 30 seconds and cycle was repeated 
for 30-35 cycles. One microliter of PCR product was diluted in 20? l formamide 
containing 1IU internal size standard (Gene Scan ROX 1000, Applied Biosystems). 
Samples were denatured for 2 min at 90°C and run on a 3700 ABI Prism Genetic 
Analyzer (Applied Biosystem). The data were visualized on a histogram and analyzed 
by using ABI Gene Scan Software (Applied Biosystems). 
 
2.9 Primers & Probes 
 
GAPDH Primers and Probes 
Human GAPDH-R 
5’-GAA-GAT-GGT-GAT-GGG-ATT-TC-3’ 
Human GAPDH-F 
5’-GAA-GGT-GAA-GGT-CGG-AGT-3’ 
Human GAPDH Probe 
VIC -5’-CAA-GCT-TCC-CGT-TCT-CAG-CC-TAMRA-3’ 
 
EGR1 Primers and Probes 
 
Human EGR1 Probe 
FAM 5’-CCC-TAC-CAG-CAC-CTG-ACC-GCA-GA-TAMRA-3’ 
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Human EGR1-F 
5’-CGG-ACA-CGG-GCG-AGC-3’ 
Human EGR1-R 
5’-TGT-TCA-GAG-AGA-TGT-CAG-GAA-AAG-A-3’ 
Mouse EGR1 Probe 
FAM 5’ATC-CCA-GCC-AAA-CGA-CTC-GGT-TGC-TAMRA-3’ 
Mouse EGR1-F 
5’-GGC-GAT-GGT-GGA-GAC-CAG-T-3’ 
Mouse EGR1-R 
5’-CGG-CCA-GTA-TAG-GTG-ATG-GG-3’ 
 
WT1 Primers and Probes 
 
Human WT1 Probe 
FAM-5-’CCT-ACC-CAG-CCT-CGA-TTT-TTT-CAT-ATT-GCA-A-TAMRA-3’ 
Human WT1-F 
5’- GAG-AAA-TCC-TCA-CTG-CCC-TGC-3’ 
Human WT1-R 
5’-CGG-CCT-CGA-AGG-TGC-AT-3’ 
Mouse WT1 Probe 
FAM-5’CGC-CCT-ACA-GCA-GTG-ACA-ATT-TAT-ACC-AAA-TG-TAMRA-3’ 
Mouse WT1-F 
5’-CCA-GGC-CCT-GCT-CCT-GA-3’ 
Mouse WT1-R 
5’-GTC-ATG-CAT-TCA-AGC-TGG-GA-3’ 
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3. Results 
 
3.1 Identification of targets gene by Microarray analysis 
 
High-density oligonucleotide microarrays were used to identify genes that were 
transcriptionally regulated by cyclin A1 in U937 cells.  As an additional control, U937-
PML-RAR?  expressing cells were used. These cells have been shown to increase 
cyclin A1 expression upon Zinc-induction of the fusion protein. Since cyclin 
overexpression might relieve serum dependence, which was usually necessary for S-
phase entry, the microarray analyses were performed in the presence of 1%, 5% or 
10% of fetal calf serum.  Total RNA was extracted from the cell lines and hybridized 
to Affymetrix U95A arrays. These arrays contain a total of ~12.500 independent 
genes with 40 oligonucleotides ascribed to each gene. Twenty of these 
oligonucleotides contain point mutations and serve as controls for specificity. 
Following hybridization, arrays were laser scanned. Primary bioinformatics analyses 
were carried out using the Affymetrix Microarray Suite 4.0 software.  Data were 
tested for reliability and were normalized with regard to signal intensity.  
 
Finally, all the data were scaled to an average of 2500 Affymetrix units. These data 
were imported into the Excel-Software (Microsoft) and further analyzed using the 
Statistical Analysis of Microarray (SAM) –Software (Stanford). This software package 
calculates the likelihood of differences in expression based on the variability of each 
gene´s expression variability compared to expression variability of the entire dataset. 
A delta value of =2.50 or of =-2.50 was regarded as significant. Overall, 726 genes 
were significantly regulated as indicated by these analyses. To increase the 
likelihood that only the most significant genes were identified and to exclude false 
positives, the number of genes was further reduced by the following criteria: To be 
regarded as induced, the overall induction in U937-cyclin A1 cells had to be greater 
than 3-fold and in each of the pairs at 1%, 5% and 10% expression of U937-cyclin A1 
had to be greater than for U937-control cells.  
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Fig. 3: Hierarchical cluster analysis of cyclin A1 regulated genes. 
Oligonucleotide microarray analyses were performed using U95A arrays that contain 
about 12,500 independent genes. Genes that were differentially expressed between 
U937-vector control and U937-Cyclin A1 cells were identified using SAM-Analysis 
and selection criteria based on the strength of induction. For details see text. 
Hierarchical cluster analysis was performed and visualized using the Cluster and 
Tree software (Stanford). 
 
For a gene to be regarded as decreased, overall repression of the gene in U937-
cyclin A1 cells had to be greater than 3-fold (induction below 0.33) and in each of the 
pairs at 1%, 5% and 10% expression of U937-cyclin A1 had to be lower compared to 
U937-control cells. These relatively strict criteria might limit the number of false 
positives. Using these criteria, 35 genes were regarded as significant with 21 being
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 induced and 14 being repressed upon cyclin A1 induction. The data were 
hierarchically clustered and the diagram is presented in Fig. 1  
Also, It was analyzed which genes were regulated by cyclin A1 and PML-RAR? , 
since these genes might be PML-RAR?  regulated via cyclin A1 (Table 4). 
Gene Cyclin A1 PML-RAR?  
 SAM Induction SAM Induction 
Cluster Incl. W27495: 31h12 Homo 
sapiens cDNA 
4.85 3.71 5.48 3.42 
cytochrome P-450 2.74 7.57 3.21 9.88 
molybdopterin synthase sulfurylase 
(MOCS3) 
3.25 3.89 2.88 4.30 
HL23 ribosomal protein homologue 20.84 3.25 2.53 5.11 
Tissue inhibitor of metalloproteinases-2 
(TIMP-2) /len=1069 
-3.84 .08 -3.46 .02 
Table 4:  Genes that are simultaneously regulated by Cyclin A1 and PML-RAR? . 
Genes identified to be regulated by cyclin A1 were analyzed for being regulated by 
PML-RAR? . Only genes that fulfilled the criteria to be regulated in the SAM 
(Significance Analysis of Microarrays) analysis (>=+2.5 or <=-2,5) and to be induced 
or repressed more than 3-fold were regarded as significant.  Four genes were 
induced by PML-RAR?  and one gene (TIMP-2) was repressed by PML-RAR?  
 
In the current study, two genes were identified, which were repressed, and also were 
known to be involved in growth regulation and tumor pathogenesis, the Wilms’ tumor 
gene and EGR1. The Wilms tumor gene was a known tumor suppressor that was 
also overexpressed in many leukemias. The Early growth reponse gene (Egr-1) was 
another growth suppressive gene. Both proteins function as transcription factors and 
the proteins bind to the similiar DNA binding sites. Finally, both are connected to the 
functions of the p53 tumor suppressor protein. For these reasons, WT-1 and Egr-1 
were selected to be further investigated in this study. 
 
3.2 Cyclin A1 regulates WT1 and EGR1 at mRNA level 
 
In microarray analysis, it was found that U937 cells overexpressing cyclin A1 
expressed lower levels of EGR1 and WT1. In order to verify the microarray results, 
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U937 cyclin A1 overexpressing and control cells were used to confirm EGR1 and 
WT1 mRNA downregulation by quantitative real-time RT-PCR.   
 
Therefore, quantitative RT-PCR was performed with U937 control and cyclin A1 
overexpressing cells cultured in the presence of 10% FCS. The expression of WT1 in 
cyclin A1 overexpressing U937 cells was reduced by 70% as compared to 
expression in U937 control cells (Fig. 4A). EGR1 expression was reduced by 15% in 
the cyclin A1 overexpressing cells relative to the control cells (Fig. 4B). Therefore, the 
expression of WT1 and EGR1 was downregulated, and confirmed that cyclin A1 was 
involved in the suppression of these two genes at the mRNA level.   
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Figure 4: WT1(A) and EGR1(B) are downregulated in U937 overexpressing 
cyclin A1 cells as compared to U937 control cells. Total RNA of U937 control and 
overexpressing cyclin A1 cells was used in quantative RT-PCR analysis to determine 
WT1 and EGR1 expression relative to their GAPDH expression.  
 
Since the microarray expression results were confirmed by quantitative RT-PCR, we  
checked if the expression of WT1 and EGR1 was upregulated in the absence of 
cyclin A1 in murine embryonic fibroblasts (MEFs). It was observed previously that UV 
irradiation induced cyclin A1 expression via a p53-dependent mechanism (Müller-
Tidow et al, unpublished data). It was also reported previously that ionizing irradiation 
induces EGR1 expression (19, 52), (18). Therefore, it was interesting to examine the 
expression of WT1 and EGR1 after UV irradiation. MEFs were treated with UV 
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irradiation and collected at different time points to monitor the alteration of these two 
genes in the presence and absence of cyclin A1.  
 
Cyclin A1-/- MEFs showed a 2-fold increase in the EGR1 level at 24hrs after UV 
irradiation, but the increase in EGR1 expression decreased over time (Fig. 5B). 
However, there was decreased WT1 expression after UV irradiation in cyclin A-/- 
during the time course (Fig. 5A). Cyclin A1+/+ MEFs showed an increase in WT1 
expression at 24hrs, which decreased over time. 
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Figure 5: WT1(A) and EGR1 (B) expression in cyclin A1 +/+ and cyclin A1 -/- 
murine embryonic fibroblast cells upon UV irradiation.  Total RNA of cyclin A1 +/+ 
and cyclin A1 -/- MEFs was prepared at different time points after UV irradiation and 
then used in quantitative RT- PCR analysis or WT1 and EGR1 expression.  
 
These data showed that cyclin A1 was possibly involved in the regulation of WT1 and 
EGR1. The U937 cell model hinted to a putative function of cyclin A1 in the regulation 
of WT1 and EGR1 expression, but in MEFs, the relation between WT1 and cyclin A1 
was not clarified.  However, EGR1 expression was induced after 24 hrs UV 
irradiation and cyclin A1 -/- cells showed a clear increase in EGR1 expression. 
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Since WT1 and EGR1 expression was so far determined only in cultured cell lines, it 
was interesting to examine the expression of WT1 and EGR1 in different tissues of 
cyclin A1+/+ and cyclin A1 -/- mice.  
 
Interestingly, bone marrow of cyclin A1 -/- mice expressed higher levels of WT1 (Fig. 
6A) and EGR1 (Fig. 6B). Moreover, in testis, liver, and ovary the expression of WT1 
and EGR1 was also increased in absence of cyclin A1 (Fig. 6C and 6D). However, in 
lung there were decreased levels of WT1 and EGR1 in cyclin A1 -/-, while EGR1 
expression in brain and spleen was also lower in cyclin A1 -/-.  
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Figure 6:  mRNA expression levels of WT1( A+C) and EGR1 (B+D) in bone 
marrow (A+B) and different organs (C+D) of cyclin A1 +/+ and cyclin A1 -/- mice. 
Expression levels of the WT1 and EGR1 were determined by quantitative RT-PCR.  
The expression levels of WT1 and EGR1 genes were standardized using expression 
of GAPDH as a standard. Expression levels were determined in triplicates and were 
shown as the mean +SE.  
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In summary, these experiment showed that cyclin A1 could lead to transcriptional 
suppression of WT1 and EGR1 under different conditions. This further substantiates 
the assumption that WT1 and EGR1 might be downstream targets of cyclin A1 and 
that cyclin A1 is involved in the regulation of tumor suppressor genes. 
 
3.3 WT1 and EGR1 protein expression in different cell lines 
 
At the mRNA level WT1 and EGR1 were found to be downregulated in U937 cells 
overexpressing cyclin A1. To investigate the effect of cyclin A1 at the protein level, 
we performed immunoblot analyses in U937 cell lines. Cyclin A1 protein was 
expressed at higher levels in U937 cells overexpressing cyclin A1 as compared to 
control cell line (Fig. 7 upper blot).  WT1 and EGR1 expression was examined in the 
same lysates of U937 control and cyclin A1 overexpressing cells. While WT1 was 
downregulated and EGR1 was not (Fig. 7 middle blot and lower blot). 
 
The two bands detected at 54-52 kDa and 42 kDa appeared to be isoform of WT1. It 
has been reported in other studies that WT1 imunoblots showed different isoforms in 
some cell lines (58, 157, 158). 
 
Figure 7: WT1, but not EGR1 was downregulated at the protein level in U937 
cells overexpressing cyclin A1.The level of cyclin A1 protein was also shown in 
this immunblot for comparison. The blots were probed with antibodies for cyclin A1, 
WT1, and EGR1 respectively and subsequently for actin. The WT1 antibody detected 
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bands 54-52 kDa and 42 kDa, EGR1 antibody at 80 kDa and the actin antibody at 42 
kDa.
 
 
No clear difference was observed for EGR1 at protein level in U937 cells 
overexpressing cyclin A1  (Fig. 7 lower blot). At mRNA level, the EGR1 showed only 
15% difference in U937 cyclin A1 overexpressing cells. 
 
Expression of WT1 and EGR1 protein was also examined in different leukemic and 
solid tumor cell lines (Fig. 8A & 8B). In NB4 and KCL22 cell line, the 42-kDa isoform 
of WT1 was clearly observed same as in U937 control and overexpressing cyclin A1. 
In the myeloid cell line ML1, the expression of WT1 was lower compared to Hela 
(human cervix carcinoma cells) and two lung cancer cell lines Hutu and SW837 (Fig. 
8A). Expression of EGR1 was observed at low levels in KCL22 (human chronic 
myeloid leukaemia cells), NB4 (human acute promyelocytic cells), ML1 (human 
myeloid cells) and Cos-7 (monkey kidney cells) (Fig. 8B). 
 
Figure 8: Expression of WT1 and EGR1 protein in different leukemic and solid 
tumor cell lines.  K562 and NIH 3t3 cell lines were used as a positive control for 
WT1 and EGR1. The blots were probed with antibodies for WT1 or EGR1, and 
subsequently for actin. 
 
 WT1 and EGR1 expression was also determined in cyclin A1+/+and cyclin A1-/- MEFs 
at protein level.  EGR1 and WT1 protein expression was significantly higher in cyclin 
A1 -/- MEFs (Fig. 9A and 9B). Interestingly, it was observed that at protein level there 
was an increase in WT1 expression, which was not detected at mRNA level (Fig. 5A). 
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The lane 1 and 3 lysates from EGR1 was used to detect for WT1 expression (Fig. 
9B). 
 
 
Figure 9: (A) Induction of EGR1 and (B) WT1 protein in cyclin-/- murine 
embryonic fibroblasts. Extracts was prepared from two different samples of murine 
embryonic fibroblasts of cyclin A1+/+ and cyclin A1-/- in EGR1 immunoblot. The same 
lysate from lane 1 and 3 was used for WT1 immunoblot. The blots were probed with 
EGR1 (80kDa) or WT1 (54-52kDa), and subsequently for actin. 
 
To summarise, it was observed that there was an increase in the protein expression 
of EGR1 in MEFs (Fig. 9A). Moreover, it was confirmed at mRNA level that EGR1 
expression was high in MEFs without UV irradiation (see control Fig. 5B). When the 
MEFs were UV irradiated, the EGR1 expression was induced 8 fold (see Fig. 5B). No  
conclusive result was obtained concerning the WT1 expression at mRNA level, 
although an increase in WT1 expression was detected in MEFs at protein levels (Fig. 
9B). 
 
3.4 WT1 isoforms inhibit colony growth 
 
Furthermore, it was interesting to see whether the WT1 and EGR1 showed any 
significant effects on colony growth in myeloid cell lines. Normal function of WT1 
correlated with the expression of WT1 with or without a certain amino acid insertion. 
The WT1 primary transcript has been described to undergo two alternatives splicing 
events, giving rise to four isoforms of mRNA (42). Alternate splicing of exon 5 
removes 17 amino acids from the middle of the protein. The other alternate splicing 
(KTS) removes 3 amino acids between the third and fourth zinc of the finger domains 
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(Fig. 13). WT1+/-, WT1-/+ isoforms, and EGR1 respectively were transfected with 
and without cyclin A1 into 32D cells to investigate differences in colony formation. 
 
 
The transfection of WT1-/+ isoform reduced the colony growth up to 75% (Fig. 10A). 
The co-transfection of WT1 isoforms with cyclin A1 did not change colony growth 
(Fig. 10A).  EGR1 was transfected with or without cyclin A1 in 32D cell line and it did 
not lead to suppression in colony growth (Fig. 10B).  
A
0,0
20,0
40,0
60,0
80,0
100,0
120,0
140,0
160,0
180,0
P
cD
N
A
3
C
yc
A
1
W
T1
+/
-
W
T1
-/+
C
yc
A
1+
W
T1
 +
/-
C
yc
A
1+
W
T1
-/+
n
u
m
b
er
 o
f 
co
lo
n
ie
s
 
B
0,00
20,00
40,00
60,00
80,00
100,00
120,00
140,00
160,00
180,00
Pc
DN
A3
Cy
cA
1
EG
R1
EG
R1
+C
ycA
1
n
u
m
b
er
 o
f 
co
lo
n
ie
s
 
Figure 10: The effect of WT1 isoforms and EGR1 with and without cyclin A1 on 
colony growth.  32D cells were transfected with pcDNA3, cyclin A1, WT1-/+, WT1 
+/- (Fig. 10A) and EGR1 (Fig. 10B). The following day, cells were seeded in triplicate 
in methylcellulose colony assays in the presence of neomycin as selection marker. 
Colonies were counted after 14 days. The result was observed in at least three 
independent experiments and is shown as the mean +SE.  
 
In this study, the U937 cells overexpressing cyclin A1 and control were used as a 
model system. U937 cells overexpressing cyclin A1 and control were used in the 
microarray analyze to detect the genes, which were regulated by cyclin A1.  
Further, it was interesting to analyze the endogenous effect of cyclin A1 on colony 
growth. Two additional isoforms of WT1 -/- and WT1 +/+ were included in the next 
experiment to determine their effect on colony growth.   
No significant difference was found in colony formation of U937 overexpressing cyclin 
A1 and control cells with WT1 +/-, WT1 +/+, WT1 -/- isoforms, but the WT1-/+ isoform 
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induced 50% reduction of colony growth in U937 cells overexpressing cyclin A1. It 
was also observed that there was a general reduction in colony formation compared 
to control vector (Fig. 11). 
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Figure 11: Colony assay in U937 control and overexpressing cyclin A1 with 
different WT1 isoforms. U937 cells were transfected with pcDNA3, WT1-/+, WT1 
+/- WT1+/+ and WT1-/-. The following day, cells were seeded in triplicate in 
methylcellulose colony assays in the presence of neomycin as a selection marker. 
Colonies were counted after 14 days. The result was observed in at least three 
independent experiments and is shown as the mean +SE.  
 
To summarize, these data showed that WT1 isoforms reduced colony growth 
formation as compared to the control vector. The addition of cyclin A1 did not further 
affect colony formation.  
 
3.5 WT1 isoform induces G1 arrest 
 
Cyclin A1 was assumed to be involved in the G1/S transition in cell cycle 
progression. Therefore, it was tested if expression of WT1-/+, WT1+/-, and EGR1 
either with or without cyclin A1 showed any change in cell cycle progression in 32 D 
cells. 
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 For cell cycle analysis, WT1-/+, WT1+/-, EGR1, and cyclin A1 were transfected in 
32D cells and stained after 24 hours with propidium iodide for cell cycle analysis by 
flow cytometry. 
The expression of the WT1-/+ lead to a cell cycle block. This block occurred in G1 to 
S phase progression in 32D cells (Fig. 12A). WT1 induced G1 cell cycle arrest. When 
 
 cyclin A1 was co-transfected with the WT1 isoforms, cyclin A1 abrogated the WT1 
growth arrest (Fig. 12A).  Either with or without cyclin A1 co-transfection, EGR1 did 
not show any change in cell cycle progression (Fig. 12B).   
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Figure 12: Effects of WT1(A) isoforms and EGR1 (B) on cell cycle regulation by 
FACS . The pcDNA3, cyclin A1, WT1+/-, WT1-/+, EGR1 were transfected with and 
without cyclin A1 in 32D cells. After 24 hours the cells were stained with propidium 
iodide, sorted by FACS, and cell cycle distribution was calculated using the ModFitL 
T V2.0 (PMac) software. The number of cells transfected in different phases was 
compared to the cells transfected with control vector. The result presented was the 
mean of three independent experiments. 
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The percentage of cells distributed in the different phases of cell cycle is shown in 
Table 5. 
 
 
 
 
 
 
Table 5: Cell cycle distribution of EGR1 and WT1 in 32D cells.  pcDNA3, WT1 +/-
, WT1-/+, EGR1 were transfected with or without cyclin A1 in 32D cells. Cell cycle 
analysis was performed using propidium iodide staining. Figures indicate the 
percentage of cells in the different phases of the cell cycle, and the ratio of cells in G1 
to cells in S and G2/M phase. Numbers in parentheses represent the +SE.  
 
To summarize, in cell cycle analysis, the WT1-/+ isoform induced G1 cell cycle arrest 
even though the difference between cells with or without control vector was only 7%. 
Furthermore, co-transfection of cyclin A1 was observed to result in the release of G1 
arrest. 
 
3.6 WT-/- isoform predominantly expressed in U937 control 
 
The WT1 primary transcript has been described to undergo two alternatives splicing 
events, giving rise to four isoforms of mRNA (42). Alternate splicing of exon 5 
removes 17 amino acids from the middle of the protein. The other alternate splicing 
event (KTS) removes 3 amino acids between third and fourth zinc of the finger 
domains (see Fig. 13). The four isoforms are produced in a constant ratio that is 
conserved throughout in different species suggesting that they have non-overlapping 
functions. It was also reported that there was an imbalance in WT1 isoforms, leading 
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to tumor development (4, 62). In order to further analyze the function of WT1 
isoforms, the ratio of the WT1 isoforms in the U937 control and in U937 
overexpressing cyclin A1 cells was examined.  
 
 
 
Figure 13:Scheme of the WT1 gene and the position of primers. The insertion 
and exclusion of the two splice inserts (17aa and KTS) generates the four isoforms 
(WT1-/-, WT1+/+, WT1+/- and WT1-/+). The forward primer (upstream of the17aa) 
was labelled with FAM (Flourescent dye phosphoramidites), the reverse primer 
(downstream of the KTS region) remained unlabelled. 
  
The original histogram showed the different isoforms of WT1 (Fig. 14). The product 
size was calculated according to an internal standard (Rox 1000, Applied 
Biosystems), which was run with each sample. WT1 isoforms were calculated as 
WT1-/- (482bp), WT1-/+(489bp), WT1+/-(528) and WT1+/+(535bp). 
 
 
Figure 14: WT-/- isoform predominantly expressed in U937 control (upper 
histogram). The PCR product was run along with internal size standard (Gene Scan 
Rox 1000) on a 3700 ABI Prism Genetic Analyzer. The data were visualized in a 
histogram and analyzed using ABI Gene Scan Software (Applied Biosystems).  
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Interestingly, WT1-/- was found in 100% of U937 control cells, whereas the other 
isoforms were absent (upper histogram). In contrast, in U937 cells overexpressing 
cyclin A1 all isoforms were present, and measured at different ratios (lower 
  
histogram). The WT1-/- isoform was present in 12 % and the WT1-/+ (24%), WT1+/-
(26%), WT1+/+(36%) isoforms were expressed.  
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Figure 15: Distribution of WT1 isoforms in U937 control and cyclin A1 
overexpressing cells. The 100 percent value represents the sum of all WT1 
isoforms detected in one cell line.  
 
In summary, these results show that the WT1 isoforms were present in different 
ratios in U937 control and overexpressing cyclin A1 cells. (26) (136). 
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Discussion 
 
The deregulation of cell cycle is a main feature of all cancers (73). Many studies on 
cancer have focused on molecules that control cell cycle progression e.g. cyclins, 
cyclin dependent kinases (Cdks) and kinase inhibitors (CKIs). In many cancers, A-
type cyclin genes are overexpressed, and protein concentrations and related kinase 
activities are often altered (9, 28, 107). 
 
Cyclin A1 is highly expressed in the majority of myeloid and undifferentiated 
haematological malignancies as well as in normal hematopoietic progenitor cells. 
It was observed that high levels of human cyclin A1 are present in acute myeloid 
leukemia cell lines (175). One potential explanation for cyclin A1 overexpression in 
AML leukemias could be that the leukemia cells that express high levels of cyclin A1 
may be arrested at the stage of differentiation when cyclin A1 is normally expressed 
(177). However, cyclin A1 is highly expressed in leukemia and its overexpression 
contributes to enhanced leukemogenesis in mice (80). 
 
In the current study, microarray analysis was used for the first time to identify the 
putative target genes, which are down- or upregulated by cyclin A1. Their functional 
relevance to AML was also analyzed. 
 
Identification of relevant target genes in the microarray data set was performed using 
a two-step procedure. In a first step, 726 genes were identified as potential targets for 
cyclin A1. The high number of genes demanded further selection. In a second step, 
only those genes were selected that were 3 fold induced or repressed in all pairs of 
the 1%, 5% and 10% of U937-overexpressing cyclin A1 cells compared to control 
cells. These criteria limited the number of identified significant genes to 35. 
  
 Within this group of significant genes, there were 14 genes repressed and 21 
induced in U937 cells overexpressing cyclin A1. They were involved in DNA repair 
system, growth regulation and also in differentiation e.g. Fen1, BRCA1, EGR1 and 
WT1 (48) (57, 90) (52). 
 
 
Discussion 37
 
In this study, two genes were selected which were downregulated by cyclin A1 and 
involved in acute myeloid leukemia (AML): EGR1 and WT1. The main interest was to  
identify and examine target genes of cyclin A1 and to analyze the common pathways 
of these genes with reference to cellular growth and differentiation 
 
 EGR1 (also known as NGFI-A, TIS8, Krox-24, and Zif268) was selected as the first 
gene. It is a member of the immediate early gene family (148) (97), (76, 82) (14).  
The EGR1 gene encodes a nuclear protein, which contains three zinc fingers of the 
C2H2 subtype (38). Structure- function analysis of the EGR1 protein suggests that it 
contains an extended transcriptional activation domain on the N-terminus and a DNA-
binding domain, consisting of three zinc finger motifs (164). EGR1 is involved in the 
regulation of cell growth and differentiation in response to signals such as mitogens, 
growth factors, and stress stimuli (52, 83). When EGR1 is induced, often displaces 
Sp1 or Sp3, other 3-zinc finger gene transcription factors from common or 
overlapping GC-rich binding sites, where Sp1 and Sp3 support basal expression of 
genes (17, 36). The GC-rich DNA-binding element for EGR1 is present in a large 
number of gene regulatory regions, including growth factors, signal transduction 
genes, transcription factors and oncogenes. Cyclin A and the thymidine kinase gene 
were shown to be regulated by EGR1 during the G0 to G1 transition (100, 103). 
However, EGR1 is induced very early in the apoptotic process and mediates the 
activation of downstream regulatory genes such as p53, and the tumor necrosis 
factor ?  (1, 110, 112). EGR1 is also reported to interact with the transcription factor c-
Jun and to modulate its activity (78). EGR1 is involved in p21Cip1 expression by 
directly interacting with a specific sequence on its gene promoter (131) and EGR1 is 
implicated as a major regulator of cell senescence (69). 
 
EGR1 is also involved in the development, growth control, and differentiation of 
hematopoietic cells. Ectopic EGR1 expression in normal hematopoietic progenitors 
stimulated development along the macrophage lineage at the expense of 
development along granulocyte or erythroid lineages (67).  Further, EGR1 target 
genes play an important role in development of progenitors from myeloid lineages 
toward macrophage differentiation (67, 81). 
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Several genes were identified which are involved in both cellular attachment to the 
extracellular matrix and in cell –cell interactions as potential targets for EGR1.The 
intracellular adhesion molecule 1 and CD44 were found to be a target for EGR1 in B 
cells (92) (34). The CD31 promoter was shown to contain Sp1 and EGR1 elements 
that conferred phorbol myristate acetate inducibility of a reporter gene to myeloid 
cells (2). EGR1 was not only involved in the development of myeloid progenitor along 
the macrophage lineage but also accelerated this process by suppressing the 
proliferative phase of the macrophage growth to differentiation developmental 
program (67). EGR1 was also involved in the growth inhibition and suppression of 
transformation of many cell types of both hematopoietic and nonhematopoietic 
origins (83). The ectopic expression of EGR1 impaired the leukemogenicity of M1 
myeloblastic leukemia cells in vivo (68). Mice lacking the EGR1 gene were not 
impaired in macrophage differentiation (74). It was suggested that other members of 
the EGR1 family of transcription factors were capable of compensating for the 
function of EGR1 in macrophage developments.  
 
This study showed that in U937 cells overexpressing cyclin A1, EGR1 expression 
was downregulated at the mRNA level. Possibly, EGR1 and cyclin A1 were 
regulating the cellular pathway through common genes, particularly those encoding 
multifunctional transcription factors such as c-jun, c-myc, c-myb and Sp1 which were 
involved in regulation of hematopoietic cell differentiation and proliferation (12, 36, 
103, 104, 150). When cyclin A1 expression was low, EGR1 expression in leukemia 
cells was induced. Cyclin A1 was involved in regulation of multifunctional 
transcription factors, which also regulated EGR1. Bone marrow, testis, liver, and 
ovary showed high expression of EGR1 in cyclin A1-/- mice and further confirmed that 
cyclin A1 was involved in EGR1 regulation. 
 
Many human tumor and leukemia cell lines express little or no EGR1 in contrast to 
their normal counterparts (51, 84). At protein level, it was found that EGR1 did not 
show any difference between U937 cyclin A1 overexpressing and control cells. It 
could be assumed that the EGR1 protein was stable and was not degraded by cyclin 
A1.  
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Different studies showed that certain types of cancer expressed high levels of EGR1, 
whereas others expressed low levels (77) (165). The current study reveals that EGR1 
expression was low in myeloid and MEF cells but its expression was high in colon 
and cervical carcinoma cell line. It was suggested that expression of EGR1 was 
varied in different tumor cell lines.  
 
In addition, UV irradiation caused an increase in expression of EGR1 in MEF cells 
thus confirming previous reports that EGR1 was involved in the DNA repair system 
(19, 130). EGR1 induced pro-apoptotic function after irradiation and was directly 
mediated by the target genes p53 and Rb (18). Cyclin A1 was involved in a DNA 
repair system, and irradiation induced apoptosis (Müller-Tidow et al, unpublished 
data) and mediated its action via a p53 dependent pathway. It could be speculated 
that enhanced levels of EGR1 protein may be needed to regulate genes involved in 
DNA repair, cell survival, and apoptosis. 
 
In the 32D cell line, the constitutive expression of EGR1 did not show any difference 
in colony formation. It was reported in different studies that EGR1 is involved to 
promote cell growth in prostate cancer cells (169) and rat kidney tumor cells (144). 
However, in breast cancer, fibrosarcoma and glioblastoma, EGR1 functioned as a 
growth suppressor (12, 51). Previous studies did also show a clear role of EGR1 as a 
growth suppressor or enhancer (12, 51, 169). It was suggested that constitutive 
EGR1 expression was affected in cell growth differently in different cell lines, what 
might suggest a tissue specific role of EGR1.  
 
It was also observed that ectopic expression of EGR1 in 32D myeloid cells did not 
show any change in cell cycle distribution. It was reported that EGR1 was involved in 
cell cycle regulation during G0 to G1 transition of certain genes e.g. cyclin A, 
thymidine kinase (100, 103, 174). In a human melanoma cell line (A375-C6), EGR1 
impedes the Interleukin-1 inducible G0-G1 growth arrest (150). In this experiment, 
cells were used from mixed population and this could be a reason that EGR1 did not 
show any effect in cell cycle. It was also suggested that EGR1 was not directly 
involved in cell cycle regulation and this could be another reason why ectopic 
expression of EGR1 did not show any effect in cell cycle analysis. 
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The second gene examined in the current study was WT1, which was repressed by 
cyclin A1. Wilms tumor gene (WT1) is known to be a tumor suppressor gene, which 
encodes a member of the Cys2-His2 zinc finger family of transcription factors. The 
WT1 gene has been reported to be expressed in normal and malignant tissues as 
expressed in urogenital tissue, kidneys, gonads, uterus, brain, spleen and 
hematopoietic precursors (145). WT1 expression has also been described in 
malignant tissues e.g. Wilms’ tumors, ovarian cancer, severe types of adult leukemia, 
many types of lung, thyroid, breast, testicular carcinoma and in melanoma.  (3, 7, 11, 
98, 99, 121, 129, 138) 
 
The WT1 gene was first identified in 1990 by genetic analysis of the region of the 
chromosome band 11p13 in which constitutional heterozygous deletions correlate 
with hereditary predisposition to Wilms’ tumor (11, 50). In mammals, exons 5 and 9 of 
WT1 are alternatively spliced, giving rise to four different splice isoforms (39). Splice 
variant 1 results in the insertion of 17 amino acids upstream of the zinc finger domain 
and enhances the transcriptional activity of protein (140). Splice variant II occurs 
within the zinc finger domain, inserting three amino acids (Lys-Thr-Ser; KTS) 
between third and fourth zinc fingers and changes the DNA binding specificity of the 
protein (RauscherIII, FJ 1990, Bicjmore, WA et al 1992). The four predominant WT1 
isoforms generated in vivo are termed WT1 +/+ (both splices 1 and 2 are present), 
WT1+/-(splice 1 present only), WT1-/+(splice 2 present only), and WT1-/- (neither 
splice present). These four isoforms display molecular masses in the range of 52-54 
kDa (102). In addition to above mentioned four isoforms of WT1, there are eight WT1 
protein isoforms generated through translation initiation at an in-frame CUG codon 
upstream of the initiator AUG resulting in WT1 protein isoforms with molecular 
masses of 60-62 kDa (8). Internal translation initiation at an in-frame AUG127 codon 
downstream of the initiator AUG generates smaller WT1 isoforms with molecular 
masses of 36-38 kDa (142). WT1 isoforms with splice1 and 2 differences have 
distinct DNA-binding and transcriptional activities (23, 140, 171). 
 
 
The WT1 zinc finger domain binds to the characteristic GC-rich EGR1 DNA-binding 
element, although with approximately 40-fold less affinity than EGR1 itself (24, 132). 
WT1 protein binds to the EGR1 DNA-binding element, which present in various 
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growth factor gene promoters such as the platelet-derived growth factor A chain 
(PDGF-A) promoter (170), p21, E-cadherin, insulin like growth factor II (IGF-II) 
promoter, and the murine colony-stimulating factor, 1(CSF-1) promoter ((23, 44). 
WT1 binding to the PDGF-A promoter region results in downregulation of this growth 
factor gene in vivo. Interestingly, WT1 can exert a dual transcriptional function.  WT1 
acts as a transcriptional repressor of the EGR1 gene in the presence of wild type 
p53, and it acts as a transcriptional activator in the absence of p53 (91). WT1 isoform 
with and without KTS play a role in sexual development by interacting with 
steroidogenic factors 1 (SF1) and Dax1 (111). In addition, WT1 binds to multiple sites 
of its own promoter region resulting in a feedback downregulation of the WT1 gene 
(140). It has been suggested by previous studies that WT1 is involved in cellular 
proliferation, differentiation, apoptosis and sex determination.  
 
Normally, WT1 is expressed in CD34+ hematopoietic progenitor cells and disappears 
during differentiation (35, 98). WT1 is overexpressed in leukemic cells in the majority 
of human acute leukemias and in the blasts crisis of chronic myeloid leukemia. Most 
commonly, heterozygous WT1 mutations are found in approximately 15% of AML 
cases and are associated with poor response to chemotherapy (37, 119). WT1 is 
overexpressed in most adult and pediatric acute leukemias, CML and advanced 
MDS. High levels of WT1 expression have adverse prognostic significance in AML 
(both adult and pediatric) and pediatric ALL (139). 
 
WT1 has been considered to be a prognostic marker in acute leukemia (5, 56).  
Immunization with WT1 peptides can raise a cytotoxic response to chemotherapy 
(37, 119). Induction of differentiation in several myeloid cell lines is associated with 
rapid decrease in WT1, and overexpression was found to interfere with the induced 
differentiation in these cells (149, 159). Thus, it is likely that WT1 has a role in 
hematopoietic differentiation. 
 
In this study, WT1 was induced both at mRNA and protein levels when cyclin A1 was 
expressed at low level. It was suggested that cyclin A1 was involved indirectly in the  
phosphorylation of genes, which bind to WT1, followed by inhibition of WT1 
expression. It was also reported that WT1 is involved in the transcriptional regulation 
of c-myc, c-myb, p21, p53 and RAR-?  (32, 46, 93) (143), which alter the 
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transcriptional regulation properties of WT1. Functionally, cyclin A1 associates with 
the cell cycle regulatory proteins Rb and E2F1 in vivo, and (59) it also interacts with 
B-myb. Cyclin A1/cdk2 posphorylates B-myb at functionally important serine and 
threonine residues at the C-terminus (106). C-myb is also involved in the 
transactivation of the human cyclin A1 promoter.   
 
Additionally, UV irradiation did not effect WT1 expression in MEF cells. Morever, it 
has been reported that treatment of HEK293 cells with UV light strongly enhanced 
transcriptional activation by the WT1 (+17aa) construct, correlating with an induction 
of endogenous Par4 expression (137). Other studies suggested that different WT1 
isoforms have overlapping function. The experimental results of this study do not rule 
out this possibility. 
 
Transfection of WT isoforms into myeloid cell lines inhibited colony formation in 
methylcellulose medium. WT1-/+ isoform was observed to have more effect in 32D 
and U937 overexpressing cyclin A1 cell lines. It was examined that transfection of 
different WT1 isoforms showed pronounced reduction in colony growth.  Different 
studies showed that WT1 was involved in growth suppression and differentiation in 
hematopoietic cells. The different isoforms of WT1 behaved differently in growth 
suppression and differentiation of hematopoietic cells. It was reported that WT1 (-
KTS) and WT1 (+KTS) affect differently growth suppression of primary hematopoietic 
cells (30, 160).  
 
WT1 -/+ was shown to induce G1 arrest in 32D cells, which further confirmed that this 
isoform was involved in different functions of myeloid cells. Different reports 
mentioned that WT1 has relevance for the induction of growth arrest and apoptosis 
(31, 94, 108). Overexpression of WT1 blocked the G1-S transition of NIH3t3 and 
induced apoptosis in F9 embryonal carcinoma cells and in an osteosarcoma cell line 
(31, 70, 71). The M1 murine myeloblastic cell line expressing no endogenous WT1 
reacts very differently to ectopic expression. Constitutive expression of the WT1 
(+KTS) form induces monocytic differentiation independent of external stimuli. 
Whereas M1 cells stably expressing the WT1 (-KTS) isoform cannot be established 
because they induce G1 arrest and/or apoptosis (108, 158). These findings also 
indicate that the effects of WT1 isoforms are different with respect to the various cell
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 backgrounds. In the current study, WT1 (+KTS) was involved in G1 arrest, which 
was contradictory to previous results. A possible explanation for this could be the 
specific background of cells. In a previous study, it was observed that overexpression 
of cyclin E/cdk2 or cyclin D1/cdk4 induced cell cycle progression into S phase, which 
is blocked by WT1 (70). In this study, the co-transfection of cyclin A1 was also 
observed to release the G1 arrest. It was suggested that cyclin A1 might interact with 
WT1 directly or indirectly during cell cycle.      
 
The WT1 splice variants are conserved in all mammals and it seems that the ratio 
between different isoforms remains constant throughout development. The combined 
expression of all splice variants might be essential for normal functioning. The 
different isoforms were investigated using capillary electropherosis of fluorescent 
labelled PCR products. Only the WT1 -/- isoform was found in the U937 control 
sample compared to U937 overexpressing cyclin A1 sample. It was further observed 
that U937 overexpressing cyclin A1 cells showed all isoforms at different ratios.  A 
mutation interfering with the ratio of WT1 (+KTS) and WT1 (-KTS) protein reportedly 
leads to the Frazier syndrome (65). Furthermore, the WT1+/+ (+17aa) and WT1-/+(-
17aa) ratio is also important, and absence of WT1 (-17aa and –KTS) showed poor 
postnatal survival and glomerular abnormalities in mice (113, 114). The current study 
is in accordance with previous findings that the isoform ratio could be depending 
upon the type and stage of cells. 
 
Taken together, several lines of evidence indicate interaction between cyclin A1 and 
the two newly identified target genes. Cyclin A1 was involved in regulating WT1 and 
EGR1 through multifunctional transcription factors and in interfering their pathways. 
The current study has set the first step to identify two cyclin A1 target genes by 
microarray analysis and examine their co-relation. 
 
WT1 and EGR1 are involved in cellular growth and differentiation in the 
hematopoietic system, and their deregulation plays a role in AML. However, much 
remains to be learned about their role in the hematopoietic system and AML.  
Apart from this, the exact role of cyclin A1 itself in the hematopoietic cell cycle and in 
the pathogenesis of acute myeloid leukemia demands further analysis. 
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